The erythrocyte sedimentation rate (ESR) is one of the most commonly used laboratory tests linked to inflammatory reactions. Historically employed for a long time, ESR remains a rapid, non-specific marker that clinicians frequently encounter. The traditional clinical interpretation focuses on how quickly erythrocytes settle in anticoagulated blood, with faster rates typically associated with acute or chronic inflammation. The study summarized here revisits ESR from a biophysical perspective to address whether a slow ESR can carry clinically relevant information.
Recent descriptions recast the sedimentation process as the collapse of a percolating gel formed by erythrocytes. This conceptual shift moves beyond a simple particle-settling view and frames ESR as a bulk structural transition of a red blood cell network. The authors combined experimental observations with physical modelling to deepen understanding of how cell–cell interactions, aggregate structures, and suspension mechanics determine sedimentation behavior. This deeper biophysical account underpins attempts to extract more precise, physiologically meaningful parameters from standard ESR measurements.
The study reports a set of clinical pictures in which ESR is systematically slow. Conditions highlighted by the authors include sickle cell disease, neuroacanthocytosis syndromes, and chronic mountain sickness. These examples illustrate that deviations toward slower-than-normal sedimentation are reproducible across distinct pathologies and may reflect specific changes in erythrocyte shape, deformability, interactions, or suspension microstructure rather than simply absence of inflammation. The authors emphasize that slow ESR has not been well-characterized previously for clinical utility; their observations aim to fill that gap.
To increase the accuracy and interpretability of ESR-derived data, the investigators combined measured ESR data with physical modelling. While the preprint outlines the integration of empirical measurements and modelling to derive new parameters, detailed experimental protocols, sample sizes, or statistical summaries are reported in the source material and supplementary files. The modelling approach treats the erythrocyte suspension as a gel-like network and uses physical principles governing collapse dynamics to link observed sedimentation kinetics to underlying hematologic and rheologic properties.
Based on their combined empirical and modelling work, the authors introduce an improved metric termed supraESR. This parameter is derived from established ESR measurement methods but incorporates modelling-derived corrections or additional metrics to enhance accuracy and clinical relevance. The supraESR is described as computable from existing, easily automated measurement workflows, meaning it can be obtained without the need for novel instrumentation. The authors propose that supraESR yields more informative readouts than the conventional ESR alone, particularly in contexts where slowed sedimentation has diagnostic significance.
A principal clinical application proposed is low-cost screening for neuroacanthocytosis syndrome, a group of rare neurodegenerative disorders that historically required complex diagnostic tests. By leveraging supraESR as a screening tool, the authors suggest an accessible, cost-effective strategy to flag patients for further confirmatory testing. More broadly, recognizing patterns of systematically slow ESR across conditions such as sickle cell disease and chronic mountain sickness could enable novel diagnostic pathways or monitoring approaches where conventional ESR interpretation would miss meaningful pathology. The preprint positions supraESR as an addition to, rather than a replacement for, established clinical and laboratory diagnostics.
The authors state that all relevant ethical guidelines were followed and that the study received ethical approval from the Ethics committee of the Aerztekammer des Saarlandes (Institutional Review Board number 51/18). They confirm that patient/participant consent was obtained and that reporting guidelines were followed. The manuscript declares no competing interests. All data produced in the study are available upon reasonable request to the authors. Funding sources listed by the authors include Saarland University, Hermann und Lilly Schilling-Stiftung, the Grenoble Alpes University foundation, and the French National Research Agency (ANR).
This work is presented as a medRxiv preprint (posted September 01, 2026) and therefore had not been peer-reviewed at the time of posting. The overview here reports the study conclusions as stated by the authors. Specific experimental details, numerical results, model equations, and validation metrics are provided in the preprint and supplementary material; readers should consult the original document or contact the authors for full methodological and quantitative information. The authors note that data and code are available on reasonable request.
The study suggests that existing ESR assays could yield greater diagnostic value when interpreted through a biophysical framework and when augmented by model-based parameters such as supraESR. Because supraESR is described as computable from standard, automatable ESR measurements, implementation in routine laboratories could be feasible without major equipment changes. However, adoption would require validation in independent cohorts and clarity about thresholds, sensitivity, specificity, and clinical pathways triggered by abnormal supraESR values—details that the preprint indicates but does not fully resolve in the summary.
The authors reframe ESR as a gel-collapse phenomenon and identify clinically relevant instances of systematically slow sedimentation. Through combined measurement and physical modelling they propose supraESR as a novel, low-cost parameter potentially useful for screening rare neurodegenerative disorders and for better interpreting ESR changes across disease states. The preprint provides ethical approvals and declares data availability; further peer review and external validation will be needed to confirm clinical utility.